TY - JOUR
T1 - Corrigendum
T2 - Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries (Front. Med., 11, (1439338), (10.3389/fmed.2024.1439338))
AU - Vitale, Antonio
AU - Palacios-Olid, Judith
AU - Caggiano, Valeria
AU - Ragab, Gaafar
AU - Hernández-Rodríguez, José
AU - Pelegrín, Laura
AU - Mejía-Salgado, Germán
AU - Zarate-Pinzón, Laura
AU - Gentileschi, Stefano
AU - Sota, Jurgen
AU - Fonollosa, Alex
AU - Carreño, Ester
AU - Gaggiano, Carla
AU - Amin, Rana Hussein
AU - Balistreri, Alberto
AU - Narváez, Javier
AU - Tosi, Gian Marco
AU - Frediani, Bruno
AU - Cantarini, Luca
AU - de-la-Torre, Alejandra
AU - Fabiani, Claudia
N1 - Publisher Copyright:
Copyright © 2024 Vitale, Palacios-Olid, Caggiano, Ragab, Hernández-Rodríguez, Pelegrín, Mejía-Salgado, Zarate-Pinzón, Gentileschi, Sota, Fonollosa, Carreño, Gaggiano, Amin, Balistreri, Narváez, Tosi, Frediani, Cantarini, de-la-Torre and Fabiani.
PY - 2024
Y1 - 2024
N2 - In the published article, there was an error in Figure 1 as published. In the Figure 1 there are several errors in the panels, which are crucial for the selection of patients included in the study. “Uveitis registry” was changed to “AIDA registry”; “Behçet's disease” was removed from the middle right hand side panel; “Behçet's disease patients with ocular involvement treated with JAK inhibitors” was changed to “Patients treated with JAK inhibitors” in the bottom right hand side panel. The corrected Figure 1 and its caption appear below. Flow-chart explaining the selection of patients included in this study starting from the total number of patients included in the AutoInflammatory Disease Alliance (AIDA) Network project. In the published article, there was an error in Table 1 as published. In Table 1, there is a typographical error in the second to last row, “Extra ocular” was changed to “Extraocular”. The corrected Table 1 and its caption appear below. Demographic, clinical and therapeutic features describing the twelve patients enrolled. Each row is referred to one patient. ANA, anti-nuclear autoantibodies; GCs, glucocorticoids; JAK, Janus Kinase; PDN, prednisone. In the published article, there was an error. There are four sentences in which there are either structural or typographical errors. A correction has been made to Patients and methods, Paragraph 1. This sentence previously stated: “international AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's disease”. The corrected sentence appears below: “International AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's syndrome”. A correction has been made to Results, Paragraph 1. This sentence previously stated: “and one from the International AIDA Network registry dedicated to Behçet's disease (10)”. The corrected sentence appears below: “and one from the International AIDA Network registry dedicated to Behçet's syndrome (10)”. A correction has been made to Treatment details, Paragraph 8. This sentence previously stated: “Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, and one on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, and seven months for the patient treated with sulfasalazine”. The corrected sentence appears below: “Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, one was on leflunomide, and one was on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, seven months for the patient in therapy with sulfasalazine, and six months for the patient treated with leflunomide”. A correction has been made to Discussion, Paragraph 6. This sentence previously stated: “The lack of Gas withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”. The corrected sentence appears below: “The lack of GCs withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
AB - In the published article, there was an error in Figure 1 as published. In the Figure 1 there are several errors in the panels, which are crucial for the selection of patients included in the study. “Uveitis registry” was changed to “AIDA registry”; “Behçet's disease” was removed from the middle right hand side panel; “Behçet's disease patients with ocular involvement treated with JAK inhibitors” was changed to “Patients treated with JAK inhibitors” in the bottom right hand side panel. The corrected Figure 1 and its caption appear below. Flow-chart explaining the selection of patients included in this study starting from the total number of patients included in the AutoInflammatory Disease Alliance (AIDA) Network project. In the published article, there was an error in Table 1 as published. In Table 1, there is a typographical error in the second to last row, “Extra ocular” was changed to “Extraocular”. The corrected Table 1 and its caption appear below. Demographic, clinical and therapeutic features describing the twelve patients enrolled. Each row is referred to one patient. ANA, anti-nuclear autoantibodies; GCs, glucocorticoids; JAK, Janus Kinase; PDN, prednisone. In the published article, there was an error. There are four sentences in which there are either structural or typographical errors. A correction has been made to Patients and methods, Paragraph 1. This sentence previously stated: “international AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's disease”. The corrected sentence appears below: “International AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to uveitis, scleritis and Behçet's syndrome”. A correction has been made to Results, Paragraph 1. This sentence previously stated: “and one from the International AIDA Network registry dedicated to Behçet's disease (10)”. The corrected sentence appears below: “and one from the International AIDA Network registry dedicated to Behçet's syndrome (10)”. A correction has been made to Treatment details, Paragraph 8. This sentence previously stated: “Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, and one on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, and seven months for the patient treated with sulfasalazine”. The corrected sentence appears below: “Four patients were receiving combination therapy with cDMARDs at the start of treatment with JAK inhibitors: two were on azathioprine, one was on leflunomide, and one was on sulfasalazine. The follow-up period while on combination therapy was three months and eleven months for the patients on azathioprine, seven months for the patient in therapy with sulfasalazine, and six months for the patient treated with leflunomide”. A correction has been made to Discussion, Paragraph 6. This sentence previously stated: “The lack of Gas withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”. The corrected sentence appears below: “The lack of GCs withdrawal in these two cases was either due to systemic disease activity or the short follow-up duration”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
UR - http://www.scopus.com/inward/record.url?scp=85207031185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85207031185&partnerID=8YFLogxK
U2 - 10.3389/fmed.2024.1489092
DO - 10.3389/fmed.2024.1489092
M3 - Comment/debate
C2 - 39346944
AN - SCOPUS:85207031185
SN - 2296-858X
VL - 11
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 1489092
ER -